GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-04-13|

Implantable Oxygen-Eating Battery to Combat Cancer

by Nai Ye Yeat
Share To

The mainstream cancer treatment, including chemotherapy and radiotherapy, often causes various side effects and intense physical suffering to the patients. Recently, a research team from Fudan University has come up with a better approach to combating cancer. 

An implantable self-charging battery that consumes oxygen in cancer cells which helps to kill them consequently is reported in the journal Science Advances.

Related article: Latest Discovery in Metabolic Pathways of T-Cells Opens New Door to Immunology Research 

An Approach to Boost Hypoxia-Activated Prodrugs Efficacy

Solid tumors, such as those that can develop in breast cancer, have a common characteristic of rapid growth, which exceeds the limitation of blood vessel reconstruction. This means that the center of many tumors can be hypoxic, with much lower oxygen levels than the surrounding tissue.  

The hypoxic microenvironment helps cancer cells to escape the host immune system as the body’s immune cells often cannot survive long enough to kill the cancerous cells. Moreover, hypoxic cells are also resistant to standard treatments like radiotherapy and chemotherapies, as there is not enough blood flow to deliver a deadly dose.

Scientists started to develop hypoxia-activated prodrugs, which are hooked to a linking chemical that ensures the drug becomes active only in a low-oxygen environment, making it less harmful to ordinary body tissues.

However, hypoxia-activated prodrugs failed in clinical trials, as solid tumors may not be evenly hypoxic or simply not hypoxic enough. The scientists aimed to create a way to make tumors more hypoxic, to give the prodrugs a better chance.  

The Battery-TPZ Implantation Show Promising Efficacy on Cancer Cells

So the researchers and their colleagues deployed a tiny, flexible battery that could partially wrap around a tumor. The battery system includes a self-charging saltwater battery and an anticancer drug called tirapazamine (TPZ). The saltwater battery identifies low-oxygen tumor microenvironments and then maintains the hypoxia in those locations until TPZ destroys the cancer cells. Since the battery regulates the tumor conditions and TPZ only targets cells in low-oxygen conditions, healthy body cells can remain unscathed.  

Researchers tested the battery system on five mice. Within two weeks, it reduced cancer tumor volumes by 90% in four of them.

The findings are impressive, however, the system deployed only in mice, and specifically targeted breast cancer. It means that the harm of battery implantation in the human body and the efficacy of other cancer cell types remains unknown. Thus, it is necessary to conduct large-scale in vivo studies and to develop better drug combinations to eradicate cancer cells.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
R&D
Revolutionizing Cancer Therapy: Insights from SK Life Science Labs Dr. Mohammad on p300 and SMARCA2 Targeted Protein Degradation Technologies
2024-03-07
Biotheus Collaborates with BioNTech for Global Development of Cancer Therapy
2023-11-08
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top